ECSP056020A - Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion - Google Patents

Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion

Info

Publication number
ECSP056020A
ECSP056020A EC2005006020A ECSP056020A ECSP056020A EC SP056020 A ECSP056020 A EC SP056020A EC 2005006020 A EC2005006020 A EC 2005006020A EC SP056020 A ECSP056020 A EC SP056020A EC SP056020 A ECSP056020 A EC SP056020A
Authority
EC
Ecuador
Prior art keywords
inhibitors
methods
fim
macrofages
migration
Prior art date
Application number
EC2005006020A
Other languages
English (en)
Inventor
Jagadish C Sircar
Sunil K C Kumar
Wenbin Ying
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of ECSP056020A publication Critical patent/ECSP056020A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Se proveen inhibidores del FIM que son útiles en el tratamiento de una variedad de trastornos, entre los que se incluye el tratamiento de condiciones patológicas asociadas con la actividad FIM. Los inhibidores de FIM tienen las siguientes estructuras: incluidos estereoisómeros, prodrogas y sales farmacéuticamente aceptables de las mismas, donde n, R1, R2, R3, R4, X y Z son como se los define a continuación. También se incluyen compuestos que contienen un inhibidor de FIM en combinación con un vehículo farmacéuticamente adecuado, así como también los métodos de uso de los mismos.
EC2005006020A 2003-02-14 2005-09-14 Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion ECSP056020A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44842703P 2003-02-14 2003-02-14

Publications (1)

Publication Number Publication Date
ECSP056020A true ECSP056020A (es) 2006-09-18

Family

ID=32908587

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006020A ECSP056020A (es) 2003-02-14 2005-09-14 Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion

Country Status (23)

Country Link
US (7) US7173036B2 (es)
EP (1) EP1594501A4 (es)
JP (1) JP2006517977A (es)
KR (1) KR20050106430A (es)
CN (1) CN1750823A (es)
AR (1) AR043190A1 (es)
AU (1) AU2004213408A1 (es)
BR (1) BRPI0407424A (es)
CA (1) CA2514862A1 (es)
CL (1) CL2008001813A1 (es)
CO (1) CO5640090A2 (es)
EC (1) ECSP056020A (es)
HR (1) HRP20050733A2 (es)
MX (1) MXJL05000031A (es)
MY (1) MY142846A (es)
NO (1) NO20054218L (es)
PE (1) PE20050274A1 (es)
PL (1) PL378113A1 (es)
RU (1) RU2005128190A (es)
TW (1) TW200418829A (es)
UY (1) UY28187A1 (es)
WO (1) WO2004074218A2 (es)
ZA (1) ZA200507170B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
CN1839133A (zh) * 2003-08-22 2006-09-27 阿文尼尔药品公司 作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用
DE102004029573A1 (de) * 2004-06-18 2005-12-29 Gambro Lundia Ab MIF-Adsorbent
DE102004042607A1 (de) * 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
WO2006102191A1 (en) * 2005-03-24 2006-09-28 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
ATE475650T1 (de) * 2005-12-05 2010-08-15 Merck Sharp & Dohme Positive allosterische chinolon-m1- rezeptormodulatoren
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
DE102006042143A1 (de) * 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
AU2007301958A1 (en) * 2006-09-29 2008-04-03 Tibotec Pharmaceuticals Ltd. Quinolinone derivatives
DE102006056739A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007061764A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102007061763A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102008013587A1 (de) * 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
NZ588033A (en) * 2008-03-20 2012-11-30 Carolus Therapeutics Inc Methods of treating a mif-mediated disorder
US20110070184A1 (en) * 2008-03-24 2011-03-24 Carolus Therpeutics, Inc. Methods and compositions for treating atherosclerosis and related condidtions
WO2009143992A1 (de) * 2008-05-29 2009-12-03 Bayer Schering Pharma Aktiengesellschaft 2-alkoxy-substituierte dicyanopyridine und ihre verwendung
WO2010040029A1 (en) * 2008-10-02 2010-04-08 Celtaxsys, Inc. Methods of modulating the negative chemotaxis of immune cells
WO2010056910A2 (en) * 2008-11-12 2010-05-20 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
WO2010065491A2 (en) * 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012142498A2 (en) * 2011-04-13 2012-10-18 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
DE102011106984B3 (de) * 2011-07-08 2012-10-11 Sartorius Stedim Biotech Gmbh Microarray-Vorrichtung für das Screenen oder Auffinden von HSP90 Inhibitoren und von Inhibitoren weiterer krankheitsrelevanter Zielstrukturen
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
CN103045608A (zh) * 2012-12-17 2013-04-17 中国水产科学研究院东海水产研究所 一种拟穴青蟹巨噬细胞移动抑制因子基因mif及其用途
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
GB2524586A (en) 2014-03-28 2015-09-30 Univ Dublin Macrophage migration inhibitory factor (MIF) inhibitors
CN104447693B (zh) * 2014-10-24 2016-08-24 苏州昊帆生物科技有限公司 喹啉酮衍生物及其制备方法和应用
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
WO2018034918A1 (en) * 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
US10414775B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
KR102767739B1 (ko) 2018-06-27 2025-02-12 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물
CN112585139B (zh) 2018-06-27 2023-12-01 百时美施贵宝公司 用作t细胞激活剂的萘啶酮化合物
CN111410659B (zh) * 2019-01-08 2023-08-15 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
KR102779311B1 (ko) 2019-03-15 2025-03-11 트렌스테라 사이언스즈 (난징), 인코포레이티드 포스포디에스테라제 억제제의 결정형, 이의 제조 방법 및 이의 용도
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
CR20220236A (es) 2019-11-28 2022-10-03 Bayer Pharma AG Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
US20230062100A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
US20230064809A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CA3162979A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
BR112022012179A2 (pt) 2019-12-23 2022-09-06 Bristol Myers Squibb Co Compostos de quinazolina substituída úteis como ativadores de célula t
KR20220119456A (ko) * 2019-12-23 2022-08-29 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 퀴놀리노닐 피페라진 화합물
CN113233990B (zh) * 2021-05-13 2022-09-23 江苏超跃化学有限公司 一种5-氯-2-氨基苯甲酸中间体的制备方法
EP4486741A4 (en) * 2022-03-01 2026-04-08 Insilico Medicine Ip Ltd Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
CN116693454A (zh) * 2023-06-06 2023-09-05 中山大学 一种取代氰基喹啉酮类化合物及其制备方法与应用
WO2025030002A2 (en) * 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54165896U (es) * 1978-05-15 1979-11-21
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
US4299814A (en) 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
US4284768A (en) 1980-07-02 1981-08-18 American Home Products Corporation 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives
EP0154454B1 (en) 1984-02-22 1991-07-03 The Wellcome Foundation Limited Cloning of dna for protozoal antigens
US5801200A (en) 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733524A (en) 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5700447A (en) 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5869534A (en) 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5733933A (en) 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
AU592753B2 (en) 1984-05-24 1990-01-25 Ciba-Geigy Ag Lymphokine in pure foem, novel monoclonal antibodies hybridoma cell lines, processes and applications
JPH0672158B2 (ja) 1984-05-24 1994-09-14 チバ−ガイギ− アクチエンゲゼルシヤフト 精製されたヒトマクロファージ遊走阻止因子
US4708937A (en) 1984-10-15 1987-11-24 Brigham & Women's Hospital Purified migration inhibitory factor also having colony stimulating factor activity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8602626D0 (en) 1986-02-04 1986-03-12 Ciba Geigy Ag Neurite-promoting factor
ES2052602T3 (es) 1986-10-03 1994-07-16 Ciba Geigy Ag Nuevos peptidos afines a las linfocinas.
US4849357A (en) 1986-10-08 1989-07-18 Miles Inc. Method for the preparation of a hydrophobic enzyme-containing composition and the composition produced thereby
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990011301A1 (en) 1989-03-17 1990-10-04 Genetics Institute, Inc. Human macrophage migration inhibitory factor
FI82144C (fi) 1989-03-22 1991-01-10 Wallac Oy Foerfarande foer samtidig bestaemning av flera ligander.
GB8915414D0 (en) 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
US5328990A (en) 1991-04-26 1994-07-12 The United States Of America As Represented By The Department Of Health And Human Services Isolation of macrophage migration inhibition factor from ocular lens
US5352660A (en) 1991-10-31 1994-10-04 Mount Sinai Hospital Corporation Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
US5624804A (en) 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US6645493B1 (en) 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
JP4708510B2 (ja) 1993-05-17 2011-06-22 サイトカイン ファーマサイエンシズ，インコーポレーテッド サイトカイン媒介毒性に関係する疾患の治療における遊走阻止因子の抑制
US5650295A (en) 1995-06-02 1997-07-22 Human Genone Sciences, Inc. Macrophage migration inhibitory factor-3
SI9400363A (en) 1994-09-19 1996-08-31 Mozetic Francky Bojana Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein
AU4365796A (en) 1994-11-16 1996-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
EP0898709A2 (en) 1996-04-18 1999-03-03 Ariad Pharmaceuticals, Inc. $i(IN VITRO) FLUORESCENCE POLARIZATION ASSAY
US5883224A (en) 1996-04-19 1999-03-16 Cytokine Sciences, Inc. Characterization of transfer factors and methods of use
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
US6413939B1 (en) 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect
DK1036192T3 (da) 1997-12-05 2003-06-10 Upjohn Co Fluorescensbaserede screeningsanalyser med høj hastighedforproteinkinaser og phosphataser
JP2002521690A (ja) 1998-07-28 2002-07-16 バイオメトリック イメージング インコーポレイテッド 細胞運動性アッセイのための装置および方法
US6214343B1 (en) 1999-05-24 2001-04-10 Ophidian Pharmaceuticals, Inc. Prevention and treatment of necrotizing enterocolitis
CA2389229A1 (en) 1999-10-29 2001-05-10 The Picower Institute For Medical Research Compounds having mif antagonist activity
EP1465660A4 (en) 2001-01-12 2005-09-21 Cytokine Pharmasciences Inc METHOD AND COMPOSITIONS FOR MODULATING THE REGULATION OF THE CYTOTOXIC LYMPHOCYTE RESPONSE BY MACROPHAGE MIGRATION HEMM FACTOR
DK1383919T3 (da) 2001-03-29 2010-11-08 Cytokine Pharmasciences Inc Fremgangsmåder og sammensætninger til anvendelse af MHC klasse II-invariant kædepolypeptid som en receptor for makrofag migrationsinhiberede faktor
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
CA2459224C (en) 2001-09-03 2012-05-08 Takeda Chemical Industries, Ltd. 1,3-benzothiazinone derivatives and the use thereof
WO2003065979A2 (en) 2001-12-05 2003-08-14 North Shore-Long Island Jewish Research Institute Methods of diagnosis, monitoring and treatment of fertility
US20040019921A1 (en) * 2001-12-19 2004-01-29 Fingerle-Rowson Gunter R. Non-human mammal with disrupted or modified MIF gene, and uses thereof
EP1500402A4 (en) 2002-04-26 2009-12-30 Takeda Pharmaceutical INHIBITOR OF CELL DEATH
EP1511736A4 (en) 2002-06-07 2006-06-07 Cortical Pty Ltd THERAPEUTIC MOLECULES AND METHOD 1
GB2405146A (en) 2002-06-07 2005-02-23 Cortical Pty Ltd Napthalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)
WO2004060881A1 (ja) 2002-12-05 2004-07-22 Takeda Pharmaceutical Company Limited １，３−ベンゾチアジノン誘導体、その製造法および用途
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7361474B2 (en) 2003-02-24 2008-04-22 United States Of America As Represented By The Department Of Veterans Affairs Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer
CN1839133A (zh) * 2003-08-22 2006-09-27 阿文尼尔药品公司 作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用

Also Published As

Publication number Publication date
WO2004074218A2 (en) 2004-09-02
CO5640090A2 (es) 2006-05-31
TW200418829A (en) 2004-10-01
NO20054218L (no) 2005-11-10
US7312220B2 (en) 2007-12-25
JP2006517977A (ja) 2006-08-03
EP1594501A4 (en) 2007-01-24
WO2004074218A3 (en) 2005-01-20
US7173036B2 (en) 2007-02-06
US20070054898A1 (en) 2007-03-08
US20070054923A1 (en) 2007-03-08
ZA200507170B (en) 2008-09-25
CN1750823A (zh) 2006-03-22
US20070270395A1 (en) 2007-11-22
US7235546B2 (en) 2007-06-26
PL378113A1 (pl) 2006-03-06
US20070238736A9 (en) 2007-10-11
CL2008001813A1 (es) 2008-08-22
UY28187A1 (es) 2004-09-30
AU2004213408A1 (en) 2004-09-02
MY142846A (en) 2011-01-14
AR043190A1 (es) 2005-07-20
RU2005128190A (ru) 2006-05-27
BRPI0407424A (pt) 2006-01-24
EP1594501A2 (en) 2005-11-16
HRP20050733A2 (en) 2005-10-31
MXJL05000031A (es) 2005-11-03
KR20050106430A (ko) 2005-11-09
US20070054922A1 (en) 2007-03-08
US20040204586A1 (en) 2004-10-14
US20070054920A1 (en) 2007-03-08
NO20054218D0 (no) 2005-09-12
US7312221B2 (en) 2007-12-25
US20070179132A1 (en) 2007-08-02
CA2514862A1 (en) 2004-09-02
PE20050274A1 (es) 2005-04-20

Similar Documents

Publication Publication Date Title
ECSP056020A (es) Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion
UY27304A1 (es) Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
UY28483A1 (es) Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migración de macrófagos y su uso en el tratamiento de enfermedades en el hombre
CR7880A (es) Derivados sustituidos de pirrolo-pirazol como inhibidores de quinasa
UY28514A1 (es) Nuevos compuestos
PA8680701A1 (es) Derivados de oxindol
ECSP034750A (es) Derivados de espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
SV2010003567A (es) Derivados bis-(sulfonilamino) en terapia 066
CR6616A (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
UY27222A1 (es) Pirazolopirimidinas como agentes terapéuticos
CR8744A (es) Compuestos terapeuticos
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
PA8631301A1 (es) Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central
ECSP10010361A (es) Derivados de piridazinona
AR030893A1 (es) Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gabaa para el tratamiento de trastornos cognitivos
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
UY27716A1 (es) Derivados de nitrosodifenilamina y composiciones farmacéuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologías que se caracterizan por estrés oxidativo.
GT200300046A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
ES2582660T3 (es) Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
SV2005001805A (es) 3-aminopirrolidinas como inhibidores de la captacion de monoamina ref. x-15735